Academic Detailing Impact on Pharma Industry Discussed in New Study Published at MarketPublishers.com20 Feb 2012 • by Natalie Aster
LONDON – While the Food and Drug Administration (FDA) has recently clamped down on what pharma can say about their drugs and introduced stringent new transparency rules, the same laws do not apply to academic detailers. And with the ever increasing use of academic detailing in the US, where the Agency for Healthcare Research and Quality (AHRQ) has poured almost USD 30 million into the practice, there are rising concerns over the underlying motivation for its use, considering tighter public drug budgets.
New research study “Academic Detailing: Pharma Fights Back” elaborated by FirstWord examines the impact the practice of academic detailing is having on the pharmaceutical industry. It questions not only the different rules for the industry and academic detailers, but under what conditions the approach works best and how pharma can fashion its response depending on whether the messages are favourable or not. The report also reveals new marketing approaches like changing compensation structures for sales staff and the increasing use of MSL teams, as well as offers true and unbiased insight into how pharma can keep up with what prescribers are hearing and how it can be managed.
Key Report Features:
- complete overview of the practice of academic detailing;
- the AHRQ’s approach given its growing body of comparative effectiveness research;
- discussion of the industry’s two-part strategy for ‘fighting back’;
- insight into adept new marketing approaches to work with academic detailing;
- four revealing case studies.
Academic Detailing: Pharma Fights Back
Published: January, 2012
Price: US$ 745,00
More new studies by the publisher can be found at FirstWord page.